Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders.
Talaris maintains corporate offices in Boston, MA, a GMP cell processing facility in Louisville, KY, and research and development laboratories in Houston, TX.
To transform the standard of care for solid organ transplant recipients and people living with severe immune and blood disorders.
To bring our transformative cell therapies to patients as quickly and safely as possible.
“From our very beginnings through to the present day, Talaris’ central focus has been improving the lives of patients. We’re proud to be leaders in the space of immune tolerance and to be leveraging our Facilitated Allo-HSCT Therapy platform to pioneer new therapeutic options in areas of high unmet medical need.”
– Scott Requadt, CEO of Talaris
The name Talaris comes from “talaria” the winged sandals of the Greek messenger God Hermes (Roman Mercury). They were said to be made by the god Hephaestus of imperishable gold and they flew the god as swift as any bird. This imagery aligns with the message of hope we bring to patients living with conditions caused by immune intolerance.
Awards and Recognition
October: Talaris was selected as a finalist for the 2022 KY Inno’s Fire Awards in the Disruptors category — described as companies that are leading the charge in new and evolving industries and/or technologies.
April: Talaris Therapeutics, Inc. was certified as a member of the AST Circle of Excellence.
May: Talaris Therapeutics, Inc. appears on Nasdaq monitor in Times Square. Talaris CEO, Scott Requadt, rings the NASDAQ closing bell to commemorate the company’s initial public offering.
April: Talaris Therapeutics Founder and Chief Scientific Officer, Dr. Suzanne Ildstad wins the Louisville Business First, 2021 Health Care Heroes Award.
March: Dr. Ildstad wins the Kentucky Chapter of the National Kidney Foundation 2021 Distinguished Physician Award.
Talaris Therapeutics Closes $115 Million Series B Financing to support ongoing Phase 3 registrational trial of Talaris’ lead product candidate FCR001 in living donor kidney transplant.
Talaris also announces FDA allowance of IND for Phase 1/2a trial of FCR001 in diffuse scleroderma.
October: Dr. Ildstad wins the University of Louisville, 2019 Epic Innovation Awards, Innovator of the Year Award
September: Founder Dr. Suzanne Ildstad and CEO Scott Requadt accept the Xconomy Big Idea Award for Talaris.
Talaris launches Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant recipients at Centers of Excellence around the U.S.
April: Regenerex relaunches as Talaris with $100 million financing and expanded leadership team to advance FCR001 through multiple later-stage clinical trials